<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Ulcer-healing Drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i741.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i741.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i741.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i1059.htm" title="Previous: Ubidecarenone">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i743.htm" title="Next: Histamine H2-antagonists">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i741">Ulcer-healing Drugs</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Ulcer-healing Drugs</b>
          has no specific interaction information.
        </p><p><b>Histamine H<sub>2</sub>-antagonists</b> belongs to
      <b>Ulcer-healing Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>









<tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b> histamine H<sub>2</sub>-antagonists reduce plasma concentration of atazanavir </b></td><td></td></tr><tr><td><a href="41001i148.htm">Cefpodoxime</a></td><td> histamine H<sub>2</sub>-antagonists reduce absorption of cefpodoxime </td><td></td></tr><tr><td><a href="41001i1180.htm">Histamine</a></td><td> histamine H<sub>2</sub>-antagonists theoretically antagonise effects of histamine—manufacturer of histamine advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td> histamine H<sub>2</sub>-antagonists reduce absorption of itraconazole </td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td> histamine H<sub>2</sub>-antagonists reduce absorption of ketoconazole </td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td> histamine H<sub>2</sub>-antagonists possibly reduce absorption of lapatinib </td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td>avoidance of  histamine H<sub>2</sub>-antagonists advised by manufacturer of posaconazole (plasma concentration of posaconazole possibly reduced)</td><td></td></tr><tr><td><a href="41001i1111.htm">Raltegravir</a></td><td> histamine H<sub>2</sub>-antagonists possibly increase plasma concentration of raltegravir—manufacturer of raltegravir advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i1163.htm">Ulipristal</a></td><td class="cBV"><b>avoidance of  histamine H<sub>2</sub>-antagonists advised by manufacturer of ulipristal (plasma concentration of ulipristal possibly reduced)</b></td><td></td></tr></tbody></table><p><b>Cimetidine</b> belongs to
      <b>Ulcer-healing Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





























































<tr><td><a href="41001i118.htm">Amiodarone</a></td><td> cimetidine increases plasma concentration of amiodarone </td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i242.htm">Amitriptyline</a></td><td> cimetidine inhibits metabolism of amitriptyline (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td> cimetidine possibly increases plasma concentration of tricyclics </td><td></td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td> cimetidine possibly enhances effects of antipsychotics </td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  cimetidine advised by manufacturer of artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i405.htm">Benzodiazepines</a></td><td> cimetidine inhibits metabolism of benzodiazepines (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td> cimetidine possibly inhibits metabolism of calcium-channel blockers (increased plasma concentration)</td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b> cimetidine inhibits metabolism of carbamazepine (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i1123.htm">Carmustine</a></td><td> cimetidine possibly enhances myelosuppressive effects of carmustine </td><td></td></tr><tr><td><a href="41001i335.htm">Chloroquine and Hydroxychloroquine</a></td><td> cimetidine inhibits metabolism of chloroquine and hydroxychloroquine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i374.htm">Chlorpromazine</a></td><td> cimetidine possibly enhances effects of chlorpromazine </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> cimetidine possibly increases plasma concentration of ciclosporin </b></td><td></td></tr><tr><td><a href="41001i233.htm">Citalopram</a></td><td> cimetidine increases plasma concentration of citalopram </td><td></td></tr><tr><td><a href="41001i423.htm">Clomethiazole</a></td><td> cimetidine inhibits metabolism of clomethiazole (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> cimetidine possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td> cimetidine possibly enhances effects of clozapine </td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> cimetidine inhibits metabolism of coumarins (enhanced anticoagulant effect)</b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i246.htm">Doxepin</a></td><td> cimetidine inhibits metabolism of doxepin (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i1030.htm">Epirubicin</a></td><td class="cBV"><b> cimetidine increases plasma concentration of epirubicin </b></td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  cimetidine given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1048.htm">Erlotinib</a></td><td class="cBV"><b>avoidance of  cimetidine advised by manufacturer of erlotinib </b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td> cimetidine increases plasma concentration of erythromycin (increased risk of toxicity, including deafness)</td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i964.htm">Escitalopram</a></td><td> cimetidine increases plasma concentration of escitalopram </td><td></td></tr><tr><td><a href="41001i1220.htm">Fampridine</a></td><td class="cBV"><b>avoidance of  cimetidine advised by manufacturer of fampridine </b></td><td></td></tr><tr><td><a href="41001i120.htm">Flecainide</a></td><td> cimetidine inhibits metabolism of flecainide (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i509.htm">Fluorouracil</a></td><td> cimetidine inhibits metabolism of fluorouracil (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i247.htm">Imipramine</a></td><td> cimetidine inhibits metabolism of imipramine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i472.htm">Isradipine</a></td><td> cimetidine increases plasma concentration of isradipine (halve dose of isradipine)</td><td></td></tr><tr><td><a href="41001i448.htm">Labetalol</a></td><td> cimetidine increases plasma concentration of labetalol </td><td></td></tr><tr><td><a href="41001i738.htm">Levothyroxine</a></td><td> cimetidine reduces absorption of levothyroxine </td><td></td></tr><tr><td><a href="41001i55.htm">Lidocaine</a></td><td class="cBV"><b> cimetidine increases plasma concentration of lidocaine (increased risk of toxicity)</b></td><td>Interactions less likely when lidocaine used topically</td></tr><tr><td><a href="41001i1122.htm">Lomustine</a></td><td> cimetidine possibly enhances myelosuppressive effects of lomustine </td><td></td></tr><tr><td><a href="41001i309.htm">Loratadine</a></td><td>manufacturer of loratadine advises  cimetidine possibly increases plasma concentration of loratadine </td><td></td></tr><tr><td><a href="41001i609.htm">Mebendazole</a></td><td> cimetidine possibly inhibits metabolism of mebendazole (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i1114.htm">Melatonin</a></td><td> cimetidine increases plasma concentration of melatonin </td><td></td></tr><tr><td><a href="41001i267.htm">Metformin</a></td><td> cimetidine reduces excretion of metformin (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i451.htm">Metoprolol</a></td><td> cimetidine increases plasma concentration of metoprolol </td><td></td></tr><tr><td><a href="41001i170.htm">Metronidazole</a></td><td> cimetidine inhibits metabolism of metronidazole (increased plasma concentration)</td><td>Interactions do not apply to topical metronidazole preparations </td></tr><tr><td><a href="41001i823.htm">Mirtazapine</a></td><td> cimetidine increases plasma concentration of mirtazapine </td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td> cimetidine increases plasma concentration of moclobemide (halve dose of moclobemide)</td><td></td></tr><tr><td><a href="41001i249.htm">Nortriptyline</a></td><td> cimetidine inhibits metabolism of nortriptyline (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i584.htm">Octreotide</a></td><td>absorption of  cimetidine possibly delayed by octreotide </td><td></td></tr><tr><td><a href="41001i85.htm">Opioid Analgesics</a></td><td> cimetidine inhibits metabolism of opioid analgesics (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> cimetidine inhibits metabolism of phenytoin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b> cimetidine reduces plasma concentration of posaconazole </b></td><td></td></tr><tr><td><a href="41001i881.htm">Pramipexole</a></td><td> cimetidine reduces excretion of pramipexole (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i125.htm">Propafenone</a></td><td class="cBV"><b> cimetidine increases plasma concentration of propafenone </b></td><td></td></tr><tr><td><a href="41001i793.htm">Propranolol</a></td><td> cimetidine increases plasma concentration of propranolol </td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td> cimetidine inhibits metabolism of quinine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  cimetidine accelerated by rifampicin (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i1190.htm">Roflumilast</a></td><td> cimetidine inhibits the metabolism of roflumilast </td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td> cimetidine possibly increases plasma concentration of saquinavir </td><td></td></tr><tr><td><a href="41001i237.htm">Sertraline</a></td><td> cimetidine increases plasma concentration of sertraline </td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td> cimetidine increases plasma concentration of sildenafil (consider reducing dose of sildenafil)</td><td></td></tr><tr><td><a href="41001i268.htm">Sulfonylureas</a></td><td> cimetidine enhances hypoglycaemic effect of sulfonylureas </td><td></td></tr><tr><td><a href="41001i292.htm">Terbinafine</a></td><td> cimetidine increases plasma concentration of terbinafine </td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b> cimetidine inhibits metabolism of theophylline (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i1027.htm">Tolazoline</a></td><td class="cBV"><b> cimetidine antagonises effects of tolazoline </b></td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td class="cBV"><b> cimetidine inhibits metabolism of valproate (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i904.htm">Zaleplon</a></td><td> cimetidine inhibits metabolism of zaleplon (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i575.htm">Zolmitriptan</a></td><td> cimetidine inhibits metabolism of zolmitriptan (reduce dose of zolmitriptan)</td><td></td></tr></tbody></table><p><b>Famotidine</b> belongs to
      <b>Ulcer-healing Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i1077.htm">Dasatinib</a></td><td> famotidine possibly reduces plasma concentration of dasatinib </td><td></td></tr><tr><td><a href="41001i1048.htm">Erlotinib</a></td><td class="cBV"><b>avoidance of  famotidine advised by manufacturer of erlotinib </b></td><td></td></tr></tbody></table><p><b>Nizatidine</b> belongs to
      <b>Ulcer-healing Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i1048.htm">Erlotinib</a></td><td class="cBV"><b>avoidance of  nizatidine advised by manufacturer of erlotinib </b></td><td></td></tr></tbody></table><p><b>Ranitidine</b> belongs to
      <b>Ulcer-healing Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i1048.htm">Erlotinib</a></td><td class="cBV"><b> ranitidine reduces plasma concentration of erlotinib—manufacturer of erlotinib advises give at least 2 hours before or 10 hours after ranitidine</b></td><td></td></tr><tr><td><a href="41001i1170.htm">Gefitinib</a></td><td class="cBV"><b> ranitidine reduces plasma concentration of gefitinib </b></td><td></td></tr><tr><td><a href="41001i1027.htm">Tolazoline</a></td><td class="cBV"><b> ranitidine antagonises effects of tolazoline </b></td><td></td></tr></tbody></table><p><b>Proton Pump Inhibitors</b> belongs to
      <b>Ulcer-healing Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>








<tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b> proton pump inhibitors reduce plasma concentration of atazanavir—avoid or adjust dose of both drugs (consult product literature)</b></td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> proton pump inhibitors possibly slightly increase plasma concentration of digoxin </td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td> proton pump inhibitors reduce absorption of itraconazole </td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td> proton pump inhibitors reduce absorption of ketoconazole </td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td> proton pump inhibitors possibly reduce absorption of lapatinib </td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td>avoidance of  proton pump inhibitors advised by manufacturer of posaconazole (plasma concentration of posaconazole possibly reduced)</td><td></td></tr><tr><td><a href="41001i1111.htm">Raltegravir</a></td><td> proton pump inhibitors possibly increase plasma concentration of raltegravir—manufacturer of raltegravir advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i1163.htm">Ulipristal</a></td><td class="cBV"><b>avoidance of  proton pump inhibitors advised by manufacturer of ulipristal (plasma concentration of ulipristal possibly reduced)</b></td><td></td></tr></tbody></table><p><b>Esomeprazole</b> belongs to
      <b>Ulcer-healing Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>









<tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> esomeprazole reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> esomeprazole possibly enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i412.htm">Diazepam</a></td><td> esomeprazole possibly inhibits metabolism of diazepam (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i1048.htm">Erlotinib</a></td><td class="cBV"><b>avoidance of  esomeprazole advised by manufacturer of erlotinib </b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b> esomeprazole possibly reduces plasma concentration of nelfinavir—manufacturer of esomeprazole advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> esomeprazole enhances effects of phenytoin </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b> esomeprazole possibly increases plasma concentration of saquinavir—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  esomeprazole reduced by tipranavir </b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td>plasma concentration of  esomeprazole possibly increased by voriconazole </td><td></td></tr></tbody></table><p><b>Omeprazole</b> belongs to
      <b>Ulcer-healing Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


















<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td> omeprazole possibly affects plasma concentration of ciclosporin </td><td></td></tr><tr><td><a href="41001i940.htm">Cilostazol</a></td><td> omeprazole increases plasma concentration of cilostazol (consider reducing dose of cilostazol)</td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td>plasma concentration of both drugs increased when  omeprazole given with clarithromycin </td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> omeprazole reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td> omeprazole possibly reduces plasma concentration of clozapine </td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> omeprazole possibly enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i412.htm">Diazepam</a></td><td> omeprazole possibly inhibits metabolism of diazepam (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i1048.htm">Erlotinib</a></td><td class="cBV"><b> omeprazole reduces plasma concentration of erlotinib—manufacturer of erlotinib advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i964.htm">Escitalopram</a></td><td> omeprazole increases plasma concentration of escitalopram </td><td></td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td> omeprazole possibly reduces excretion of methotrexate (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b> omeprazole reduces plasma concentration of nelfinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> omeprazole possibly enhances effects of phenytoin </td><td></td></tr><tr><td><a href="41001i1111.htm">Raltegravir</a></td><td class="cBV"><b> omeprazole increases plasma concentration of raltegravir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b> omeprazole increases plasma concentration of saquinavir—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td>plasma concentration of  omeprazole possibly reduced by St John's wort </td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td> omeprazole possibly increases plasma concentration of tacrolimus </td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  omeprazole reduced by tipranavir </b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td>plasma concentration of  omeprazole increased by voriconazole (consider reducing dose of omeprazole)</td><td></td></tr></tbody></table><p><b>Lansoprazole</b> belongs to
      <b>Ulcer-healing Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  lansoprazole possibly reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td> lansoprazole possibly reduces antiplatelet effect of clopidogrel </td><td></td></tr><tr><td><a href="41001i1048.htm">Erlotinib</a></td><td class="cBV"><b>avoidance of  lansoprazole advised by manufacturer of erlotinib </b></td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td>plasma concentration of  lansoprazole possibly increased by fluvoxamine </td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b> lansoprazole possibly increases plasma concentration of saquinavir—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i755.htm">Sucralfate</a></td><td>absorption of  lansoprazole possibly reduced by sucralfate </td><td></td></tr></tbody></table><p><b>Pantoprazole</b> belongs to
      <b>Ulcer-healing Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




<tr><td><a href="41001i865.htm">Clopidogrel</a></td><td> pantoprazole possibly reduces antiplatelet effect of clopidogrel </td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td> pantoprazole possibly enhances anticoagulant effect of coumarins </td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1048.htm">Erlotinib</a></td><td class="cBV"><b>avoidance of  pantoprazole advised by manufacturer of erlotinib </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b> pantoprazole possibly increases plasma concentration of saquinavir—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Rabeprazole</b> belongs to
      <b>Ulcer-healing Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i865.htm">Clopidogrel</a></td><td> rabeprazole possibly reduces antiplatelet effect of clopidogrel </td><td></td></tr><tr><td><a href="41001i1048.htm">Erlotinib</a></td><td class="cBV"><b>avoidance of  rabeprazole advised by manufacturer of erlotinib </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b> rabeprazole possibly increases plasma concentration of saquinavir—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Sucralfate</b> belongs to
      <b>Ulcer-healing Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>














<tr><td><a href="41001i478.htm">Cardiac Glycosides</a></td><td> sucralfate possibly reduces absorption of cardiac glycosides </td><td></td></tr><tr><td><a href="41001i195.htm">Ciprofloxacin</a></td><td> sucralfate reduces absorption of ciprofloxacin </td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> sucralfate possibly reduces absorption of coumarins (reduced anticoagulant effect)</b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td> sucralfate reduces absorption of ketoconazole </td><td></td></tr><tr><td><a href="41001i753.htm">Lansoprazole</a></td><td> sucralfate possibly reduces absorption of lansoprazole </td><td></td></tr><tr><td><a href="41001i840.htm">Levofloxacin</a></td><td> sucralfate reduces absorption of levofloxacin </td><td></td></tr><tr><td><a href="41001i738.htm">Levothyroxine</a></td><td> sucralfate reduces absorption of levothyroxine </td><td></td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td> sucralfate reduces absorption of moxifloxacin </td><td></td></tr><tr><td><a href="41001i197.htm">Norfloxacin</a></td><td> sucralfate reduces absorption of norfloxacin </td><td></td></tr><tr><td><a href="41001i198.htm">Ofloxacin</a></td><td> sucralfate reduces absorption of ofloxacin </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> sucralfate reduces absorption of phenytoin </b></td><td></td></tr><tr><td><a href="41001i371.htm">Sulpiride</a></td><td> sucralfate reduces absorption of sulpiride </td><td></td></tr><tr><td><a href="41001i209.htm">Tetracyclines</a></td><td> sucralfate reduces absorption of tetracyclines </td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td> sucralfate possibly reduces absorption of  theophylline (give at least 2 hours apart)</td><td></td></tr></tbody></table><p><b>Tripotassium Dicitratobismuthate</b> belongs to
      <b>Ulcer-healing Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i209.htm">Tetracyclines</a></td><td> tripotassium dicitratobismuthate reduces absorption of tetracyclines </td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_41001i743"><a href="41001i743.htm" title="Histamine H2-antagonists">Histamine H<sub>2</sub>-antagonists</a></li><li id="_41001i751"><a href="41001i751.htm" title="Proton Pump Inhibitors">Proton Pump Inhibitors</a></li><li><a href="41001i755.htm" title="Sucralfate">Sucralfate</a></li><li><a href="41001i756.htm" title="Tripotassium Dicitratobismuthate">Tripotassium Dicitratobismuthate</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i1059.htm">Previous: Ubidecarenone</a> | <a class="top" href="41001i741.htm#">Top</a> | <a accesskey="]" href="41001i743.htm">Next: Histamine H<sub>2</sub>-antagonists</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>